Drugs / TUTI-16
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01335191 | Jun 2011 → Jun 2012 | HIV infectious disease | Thymon, LLC | Completed | Missed primary |
| Phase 1/2 | NCT01144026 | Sep 2010 → Apr 2011 | HIV infectious disease | Thymon, LLC | Completed | No outcome recorded |
| Phase 1/2 | NCT00848211 | Feb 2009 → May 2010 | HIV infectious disease | Thymon, LLC | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TUTI-16 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01335191 ↗ |
| Known as | Thymon Universal Tat Immunogen | “The Thymon Universal Tat Immunogen (TUTI-16) is a fully synthetic, self-adjuvanting lipopeptide vaccine that is water soluble and administered by subcutaneous injection.” NCT00848211 ↗1“The Thymon Universal Tat Immunogen (TUTI-16) is a fully synthetic, self-adjuvanting lipopeptide vaccine that is water soluble and administered by subcutaneous injection.” NCT01144026 ↗ |
| Action | Inhibit | “immunological blockade of Tat” PMID 23095869 ↗ Oct 2012 |
| Modality | Vaccine | “TUTI-16 is a synthetic universal HIV-1 Tat epitope vaccine” PMID 22336878 ↗ Feb 2012 |
| Route | Subcutaneous | “subcutaneously administered TUTI-16” NCT00848211 ↗ |